Literature DB >> 9217660

Therapeutic approaches to genital warts.

K R Beutner1, A Ferenczy.   

Abstract

Although many treatments are available for genital warts caused by human papillomavirus (HPV), none are uniformly successful in the treatment of this disease. Most current treatment options work by destroying affected tissue, either by a cytotoxic or a physically ablative mode of action. Interferons have antiviral, antiproliferative, and immunomodulatory activities, but these have not translated into a high level of cure rates against warts. With all current treatments, recurrent warts are common. Therapies currently being investigated include a 5-fluorouracil/epinephrine collagen gel that achieves high concentrations of 5-fluorouracil at the site of injection. Other new treatment modalities focus on activating the host's immune system or improving the delivery of therapeutic compounds to the affected site. Imiquimod, a novel immune-response modifier, induces interferon and a number of other endogenous cytokines. A cream formulation containing 5% imiquimod resulted in good total clearance rates and generally tolerable side effects in controlled clinical trials of patients with external genital warts. Perhaps the most effective means for managing HPV disease would be a vaccine that prevents the occurrence of genital warts. Although it is unlikely that such a vaccine will be introduced in the near future, preliminary studies indicate that it may be possible to develop suitable prophylactic and therapeutic vaccines.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9217660     DOI: 10.1016/s0002-9343(97)00181-2

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  18 in total

1.  Human papillomaviruses as therapeutic targets in human cancer.

Authors:  Karin Hellner; Karl Münger
Journal:  J Clin Oncol       Date:  2011-01-10       Impact factor: 44.544

2.  Programmed death-1 (PD-1)-dependent functional impairment of CD4(+) T cells in recurrent genital papilloma.

Authors:  Dong-Yeop Chang; Sang Hoon Song; Sooseong You; Jino Lee; Jihye Kim; Vito Racanelli; Hwancheol Son; Eui-Cheol Shin
Journal:  Clin Exp Med       Date:  2013-07-04       Impact factor: 3.984

Review 3.  Viral infections of the gastrointestinal tract.

Authors:  R W Goodgame
Journal:  Curr Gastroenterol Rep       Date:  1999-08

4.  Identification of inhibitors to papillomavirus type 16 E6 protein based on three-dimensional structures of interacting proteins.

Authors:  James D Baleja; Jonathan J Cherry; Zhiguo Liu; Hua Gao; Marc C Nicklaus; Johannes H Voigt; Jason J Chen; Elliot J Androphy
Journal:  Antiviral Res       Date:  2006-04-21       Impact factor: 5.970

5.  The immune response modifier imiquimod requires STAT-1 for induction of interferon, interferon-stimulated genes, and interleukin-6.

Authors:  R L Bottrel; Y L Yang; D E Levy; M Tomai; L F Reis
Journal:  Antimicrob Agents Chemother       Date:  1999-04       Impact factor: 5.191

Review 6.  Topical imiquimod: a review of its use in genital warts.

Authors:  C M Perry; H M Lamb
Journal:  Drugs       Date:  1999-08       Impact factor: 9.546

7.  Alpha interferon augments cidofovir's antiviral and antiproliferative activities.

Authors:  Jeffrey A Johnson; J David Gangemi
Journal:  Antimicrob Agents Chemother       Date:  2003-06       Impact factor: 5.191

Review 8.  [Virus-induced anorectal diseases. Condylomata acuminata and herpes simplex].

Authors:  V Wienert
Journal:  Hautarzt       Date:  2004-03       Impact factor: 0.751

9.  Randomised controlled trial and economic evaluation of podophyllotoxin solution, podophyllotoxin cream, and podophyllin in the treatment of genital warts.

Authors:  C J N Lacey; R L Goodall; G Ragnarson Tennvall; R Maw; G R Kinghorn; P G Fisk; S Barton; I Byren
Journal:  Sex Transm Infect       Date:  2003-08       Impact factor: 3.519

10.  Trial watch: FDA-approved Toll-like receptor agonists for cancer therapy.

Authors:  Erika Vacchelli; Lorenzo Galluzzi; Alexander Eggermont; Wolf Hervé Fridman; Jerome Galon; Catherine Sautès-Fridman; Eric Tartour; Laurence Zitvogel; Guido Kroemer
Journal:  Oncoimmunology       Date:  2012-09-01       Impact factor: 8.110

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.